



Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD)–European Society of Gynaecologic Oncology (ESGO)–Gynecologic Cancer InterGroup (GCIg)–International Society for the Study of Trophoblastic Diseases (ISSTD)

Christianne Lok, MD, PhD¹ ; Nienke van Trommel, MD, PhD¹ ; Elena Ioana Braicu, MD, PhD² ; Francois Planchamp, PhD³; Ross Berkowitz, MD, PhD⁴; and Michael Seckl, MD, PhD⁵ ; on behalf of the EOTTD-ESGO-GCIg-ISSTD Guideline Committee

DOI <https://doi.org/10.1200/JCO-24-02326>

ABSTRACT

Gestational trophoblastic diseases (GTDs) are a group of pregnancy-related premalignant and malignant diseases with generally a favorable prognosis when treated adequately. Many different treatment protocols exist worldwide. To our knowledge, this is the first set of global consensus-based guidelines for GTD. Four international organizations (European Organisation for the Treatment of Trophoblastic Diseases, European Society of Gynecologic Oncology, Gynecologic Cancer InterGroup, and International Society for the Study of Trophoblastic Diseases) delegated 53 expert GTD clinicians from 31 countries who formulated nine consensus-based definitions and the minimum criteria required to be a GTD center. Furthermore, 18 flow diagrams were developed to diagnose, treat, and follow up all forms of primary or recurrent GTD. The definitions and flow diagrams were drafted and adapted in consecutive (online) meetings until consensus was reached followed by an external review process. Here, the final guidelines are presented together with the available supporting evidence from the literature.

ACCOMPANYING CONTENT

Appendix

Accepted March 14, 2025

Published May 13, 2025

J Clin Oncol 43:2119-2128

© 2025 by American Society of
Clinical Oncology



[View Online
Article](#)

INTRODUCTION

Gestational trophoblastic diseases (GTDs) are a group of rare premalignant and malignant diseases characterized by their origin in trophoblastic cells. Premalignant forms are complete (CHM), partial hydatidiform moles (PHM), and atypical placental site nodules (APSNs). Malignant forms are called gestational trophoblastic neoplasia (GTN) and include invasive mole, choriocarcinoma, placental site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (ETT). Although GTD is considered a rare disorder, based on the current world population, we estimate that annually 220,000 women are diagnosed globally including 22,000 with GTN.

GTN is highly curable when treated adequately. However, patients benefit from dedicated teams, multidisciplinary team (MDT) meetings, and, in complex cases, cross-border discussions.^{1,2} Referral to experts is not possible everywhere considering geographic hurdles and socioeconomic disparities between and within countries. Currently, 50% of all people live in low- or middle-income countries (LMICs).^{3,4} Therefore, GTD is often managed in low-resource settings where options for diagnostics and treatment are limited.

Many guidelines are formulated for and by medical specialists from high-income countries, but these do not necessarily serve LMICs well with their distinct health care settings. In addition, guidelines should preferably be based on high levels of evidence. However, in GTD, large-scale prospective randomized studies are lacking because of its rare occurrence. The absence of such data has led to differences in GTD treatment worldwide. Previously developed European guidelines were consulted many times but did not take the worldwide disparities into account nor covered all aspects of GTD care yet.⁵ Here, we present the globally agreed guidelines covering nearly all aspects of GTD care applicable everywhere.

METHODOLOGY, SEARCH STRATEGY, AND SELECTION CRITERIA

Guidelines were developed using a five-step process as defined by the European Society of Gynaecological Oncology (ESGO) Guideline Committee Standard Operative Procedures manual (Appendix [Fig A1](#), online only). Strengths of the process include a multidisciplinary international development approach and a robust external review process.

Nomination of the Multidisciplinary International Development Group

Four scientific organizations—ESGO, Gynecologic Cancer Intergroup (GCIg), International Society for the Study of Trophoblastic Diseases (ISSTD), and European Organisation for the Treatment of Trophoblastic Diseases (EOTTD)—nominated 53 experts (Appendix 1) involved in the management of GTD including medical and gynecologic oncologists, obstetricians, pathologists, geneticists, radiologists, and clinical chemists from 31 countries representing all continents.

Identification of Scientific Evidence

Literature was systematically reviewed and critically appraised. Relevant studies published between January 2019 and December 2022 were selected to complete the search of the previous European guideline,⁵ which was carried out using the MEDLINE database. Bibliography was supplemented by additional older relevant references identified by members of the Expert Panel. The search strategy excluded publications in other languages than English, editorials, letters, and preclinical in vitro and in vivo studies. The reference list of each identified article was reviewed for other potentially relevant articles.

Formulation of Guidelines

The Expert Panel members drafted guidelines for assigned topics. The guidelines were discussed and retained if they were supported by sufficiently high-level scientific evidence and/or when consensus was reached among experts at a predefined level of at least two third of votes.

In five sessions between October 2022 and November 2023, 18 flow diagrams, nine definitions, and agreement for the minimum requirements for a GTD center were developed. Every flow diagram was discussed and adjusted until consensus was reached.

To generate guidelines applicable worldwide, flow diagrams were divided into minimal requirements and additional practice points including best practices. Minimal requirements should be possible everywhere in the world. Practice points and best practices should be considered but are acknowledged as not generally applicable depending on geographic location and socioeconomic situation.

FIGO 2000 scoring and staging classifications were used to determine the score and stage of GTN (Appendix Tables A1 and A2, online only).⁶

External Evaluation of the Guidelines—International Review

A multidisciplinary geographically diverse external review panel was established. The flow diagrams and definitions were sent to 63 experts, and 24 forms were returned (Appendix Table A6). Responses were discussed, and subsequent

adjustments of the guidelines were consensus-based as previously defined.

FINALIZED GTD DEFINITIONS AND GUIDELINES

Definitions for GTD and Minimum GTD Center Requirements

Definitions are essential for research and clinical practice to enable selection of patients for the right treatment and comparison of data between different centers. Appendix Table A3 shows nine new or reconfirmed consensus-based definitions. Furthermore, the minimum requirements for a GTD center were defined (Appendix Table A4). We recognize that it is not possible everywhere in the world to establish a GTD center yet. In the flow diagrams, recommendations are made when to contact a GTD center. If a GTD center is not available, this advice can also be read as to contact a (inter)national GTD expert or to discuss the patients in a MDT of GTD experts.

Diagnostic and Management Pathways

Suspected Hydatidiform Mole and Transformation to GTN

Hydatidiform mole (HM) can be suspected when severe hyperemesis or symptoms of hyperthyroidism occur (Fig 1). However, most patients present with vaginal bleeding or are asymptomatic and undergo first trimester ultrasound (US).⁷ While imaging may point to a diagnosis of HM pregnancy, histologic examination of products of conception is required. High serum human chorionic gonadotropin (hCG) levels may increase suspicion for the diagnosis. Thyroid function tests should be measured to exclude hyperthyroidism. The role of Doppler US is still unclear but is being investigated in the TITANIUM study.⁸ With suspected HM, US-guided suction




FIG 1. Diagnostic and management pathway for (first) HM. ^aBest practice. CXR, chest X-ray; hCG, human chorionic gonadotropin; HM, hydatidiform mole; US, ultrasound.




FIG 2. Diagnostic pathway for (suspected) HM to GTN. ^aBest practice. CHM, complete hydatidiform mole; GTD, gestational trophoblastic disease; GTN, gestational trophoblastic neoplasia; hCG, human chorionic gonadotropin; HM, hydatidiform mole; PHM, partial hydatidiform moles.

curettage should be performed to ensure complete emptying of the cavity and avoid perforation. As these procedures potentially lead to significant blood loss, blood should be available preoperatively. Where possible, rhesus-negative women should receive anti-D immunization. There was no consensus on using cervical ripening before the procedure, and there is no literature to recommend either in favor or against this. Sometimes, hysteroscopic resection of residual tissue is an option. In older women without a wish to preserve their fertility, a hysterectomy can be considered.^{9,10} In optimal settings, tissue can be bi-banked and used for research or genetic testing (Fig 1).

Histologic examination is the basis for the diagnosis of either PHM or CHM. Differentiation between hydropic miscarriage, CHM and PHM can be difficult, and review by an experienced pathologist or ancillary techniques can be helpful.¹¹ These may include genetic analysis to confirm the type of molar pregnancy. After diagnosis of an HM, serum hCG should be monitored at least once every 2 weeks until normalization preferably using an hCG assay advised by the GTD center or centrally performed in a reference laboratory. PHM requires one more confirmatory normal hCG value before the patient can be discharged from monitoring. Serum hCG is mostly checked monthly up to 6 months after CHM although the risk of recurrence is very small.⁹ Plateauing or rising of hCG levels suggests development of GTN (Fig 2).

Unexplained Persistent Low-Level Elevated hCG

Low unexplained hCG can be a diagnostic dilemma requiring a structured workup (Fig 3). Careful history taking is

necessary to summarize medical and obstetric history and exclude exogenous hCG use. If there are no signs of pregnancy or retained products of normal conception on US, a negative urine hCG is suggestive of a false-positive serum result because of assay-interfering molecules such as human antimouse antibodies. Reference laboratories can advise on the use of another hCG assay, dilution testing, or perform a test with addition of blocking agents.¹² A true-positive hCG blood test requires measurement of additional tumor markers for germ cell tumors, hormones to identify menopause/pituitary hCG, and kidney function to exclude renal failure. Familial elevated hCG is a rare inheritable syndrome where mutated nonfunctional forms of hCG are produced. The diagnosis necessitates hCG measurements in parents.^{13,14}

Combined oral contraceptives will normalize hCG in the case of menopausal-induced pituitary hCG production. However, vascular thromboembolism in menopausal women with other risk factors can make gonadotropin-releasing hormone a better option. Functional hCG levels >50 IU/L will normally suppress ovulation, whereas nonfunctional hCG does not exert this effect. Serial weekly pelvic US and hormone profiling will reveal whether ovulation occurs. After exclusion of assay-interfering molecules, pituitary hCG, and elevated hCG in renal failure, extensive imaging is required to localize potential hCG-producing gestational or nongestational tumors. Sometimes, a fluorodeoxyglucose-positron emission tomography-computed tomography (FDG-PET-CT) can help.




FIG 3. Diagnostic pathway unexplained persistent low-level elevated hCG. ^aBest practice. CT, computed tomography; FSH, follicle-stimulating hormone; GFR, glomerular filtration rate; GTD, gestational trophoblastic disease; hCG, human chorionic gonadotropin; HRT, hormone-replacement therapy; LH, luteinizing hormone; MRI, magnetic resonance imaging; PET, positron emission tomography; US, ultrasound.

Twin Pregnancies Comprising a CHM With a Normal Cotwin

Twin pregnancy comprising suspected CHM with a cotwin is estimated to occur in 1:20,000–100,000 pregnancies (Appendix Fig A2).¹⁵ If expert US reveals an abnormal cotwin fetus, termination of pregnancy is often chosen, but if the fetus appears to be normal, this will cause a dilemma. Early termination does not decrease the risk of subsequent GTN, and although maternal complications such as pre-eclampsia occur more often, these can be managed as usual with a 40%–60% chance of a healthy baby. Whatever the patient's choice, tissue should be obtained after the end of the pregnancy for histology to confirm the diagnosis and allow genetic analysis. Early pregnancy termination should be performed by suction curettage. In late pregnancy, termination is more complex and depends on gestational age, size of uterus, and maternal risks. Ongoing pregnancies should be managed in high-risk obstetric units with regular clinical follow-up and monitoring to detect early onset of pre-eclampsia. Serial hCG and US help to assess the degree of molar overgrowth and fetal compromise. PHM with

coexisting fetus is extremely rare and requires counseling on maternal and fetal risks to determine how to proceed.

Low-Risk GTN Staging/Scoring Investigations and Treatment

After diagnosis of GTN, the extent of disease should be determined using a chest X-ray (CXR) and pelvic US (Fig 4).^{16,17} The number of metastases is calculated based on visible metastases on the CXR. Small lung metastases <1 cm can be missed with CXR, but this does not appear to influence the outcome of treatment.¹⁸ If lung metastases are found on CXR, CT thorax is required. If lung metastases are ≥1 cm, magnetic resonance imaging (MRI) brain plus CT or MRI of abdomen is required to assess further potential metastatic disease sites. The presence of lung metastases increases the risk of brain involvement. MRI of pelvis can be helpful to assess pelvic disease. PET-CT should not be routinely performed. In case of very high hCG concentrations (eg, >400,000 IU/L), even in the absence of metastases on CXR, the risk of metastases elsewhere is increased and additional imaging could be considered.¹⁹ Imaging and




FIG 4. Postmole GTN staging. ^aBest practice. CT, computed tomography; CXR, chest X-ray; GTD, gestational trophoblastic disease; GTN, gestational trophoblastic neoplasia; hCG, human chorionic gonadotropin; MRI, magnetic resonance imaging; TFT, thyroid function test; US, ultrasound.

measurement of hCG levels to calculate FIGO score should be performed just before the start of treatment.

First choice of treatment depends on the FIGO score.²⁰ Low-risk GTN with a score of ≤ 6 is treated with monotherapy. High-risk and ultrahigh-risk GTN requires treatment with multiagent chemotherapy in a referral center (Appendix Fig A3).

After the diagnosis of low-risk GTN, single-agent chemotherapy can consist of either methotrexate (MTX) with folinic acid (FA) rescue (MTX/FA) or actinomycin-D (Act-D; Fig 5, Appendix Table A5). Outcomes of both treatments are excellent²¹ with the once every 2 weeks intravenous Act-D having a higher primary complete response (70%–94%) than an intramuscular (IM) MTX regimen^{22,23} in two studies. However, the IM MTX regimen used is considered to be underdosed. Indeed, in the only randomized phase III trial available using adequate MTX dosing, the complete response rates of MTX/FA and Act-D were not significantly different (88% and 79%, respectively) and showed a 100% overall survival.²⁴ A secondary curettage can be considered as prospective research showed a cure rate of GTN of 40% independent of endometrial thickness.²⁵ Multiple curettages should be avoided to prevent endometrial scarring. Profuse bleeding may stop after performing a second curettage. Hysterectomy is an alternative treatment in women with completed families and disease confined to the uterus.²⁶

If resistance or toxicity develops to the first single agent, then the other single-agent or multiagent chemotherapy

should be started based on the hCG level²⁷ after reimaging. Act-D is able to induce remission in 74% of the patients with MTX resistance²⁸ and even 93% in patients with an hCG level of $\leq 1,000$ IU/L.²⁴ The chances of success with the second agent falls with higher hCG levels.²⁴ Carboplatin as an alternative single-agent therapy was not very efficacious and is therefore not recommended.^{29,30} Non-randomized phase II data suggest that avelumab will induce remission in 53% of patients failing one single-agent therapy and may be an option in some centers.³¹ In patients with a FIGO score of 5–6, the chance of sustained remission with one or two sequential single agents is 60%. However, in three situations, combination-agent chemotherapy should be considered from the outset: (1) histology of metastatic choriocarcinoma, (2) no metastatic disease or choriocarcinoma but with a pretreatment hCG concentration of $>410,000$ IU/L, and (3) metastases or choriocarcinoma and a pretreatment hCG concentration of $>150,000$ IU/L.³² After normalization of the hCG, at least two courses of MTX or Act-D should be given. Some centers advocate three courses as a study comparing two versus three courses showed a lower recurrence rate (4% v 8%) after three courses.³³ However, groups were not entirely comparable and other reports suggest that two consolidation courses are sufficient.^{33,34}

High- and Ultrahigh-Risk Staging Investigations and Treatment

Incidence of high- and ultrahigh-risk GTN is low, management is complex, and treatment should be given in a GTD




FIG 5. Treatment of low-risk GTN to remission. ^aBest practice. ^bIf hCG plateaus/rises using serial local hCG test results and $\leq 1,000$ IU/L, consider switch to other single agent, but if $>1,000$ IU/L, consider EMA/CO. For completely resected (low-risk) choriocarcinoma with hCG falling by half every 2 days to normal, no additional treatment is required. ^cOr other standard multichemotherapy schedule as advised by the GTD center. Avelumab can be an option in some countries to prevent multiagent chemotherapy. Act-D, actinomycin-D; EMA/CO, etoposide, MTX, Act-D, cyclophosphamide, and vincristine; GTD, gestational trophoblastic disease; GTN, gestational trophoblastic neoplasia; hCG, human chorionic gonadotropin; US, ultrasound, MTX, methotrexate.

center (Fig 6 and Appendix Fig A4). More extensive investigation including MRI of head and pelvis and CT of chest and abdomen is necessary. Metastases are often highly vascular, and biopsies can cause life-threatening bleeding and should only be obtained when it is safe. High-risk GTN requires treatment with multiagent chemotherapy. Etoposide, MTX, and Act-D (EMA) alternating with cyclophosphamide and vincristine (CO [EMA/CO]; Appendix Table A5) are often used, but other schedules are possible. On starting chemotherapy, severe bleeding and metabolic disturbance may arise and can be mitigated by using low-dose etoposide and cisplatin (EP) chemotherapy before starting EMA/CO.³⁵ If bleeding occurs, embolization of the affected vessels is often helpful. Adapted chemotherapy is required for brain metastases, and neurosurgical intervention may be needed.³⁶

There is no consensus because of lack of evidence on the exact number of consolidation courses, but the minimum recommended is two cycles. Survival rates are $>96\%$.³⁷

In ultrahigh-risk GTN (FIGO score ≥ 13), 1-3 cycles of low-dose EP are frequently used for the reasons discussed above (Appendix Fig A4). After this, it is usually safe to commence schedules such as EMA/CO or EMA/EP. In China, floxuridine, Act-D, etoposide, and vincristine (FAEV) are often used as an alternative effective regimen.³⁸ In the presence of CNS

metastases, the dosage of MTX should be increased.³⁶ Some centers add intrathecal MTX (IT-MTX) although there is no consensus on the value of IT-MTX. Neurosurgery may be indispensable to control raised intracranial pressure, remove bleeding metastases, or insert an Ommaya reservoir to facilitate the delivery of IT-MTX. Stereotactic radiation therapy can be considered for vital brain lesions at the end of treatment, which are not safe to remove surgically. In the case of nonmolar choriocarcinoma, an increased risk of CNS metastases (20%) has been reported, and therefore, routine imaging of the CNS should be performed.³⁶ After normalization of hCG, 3-4 courses of consolidation should be administered. Survival up to 80%-85% has been reported.^{37,39}

Diagnosis and Management of APSN, PSTT, and ETT

APSN was first described in 2015 (Appendix Fig A5).⁴⁰ Since then, more cases have been identified and the WHO introduced it in their classification, but diagnostic criteria remain unclear and not well defined.⁴¹ Molecular profiling suggests that APSN should be considered a transitional stage between PSN and ETT.⁴²

Because of its association with PSTT or ETT in 14%, pelvic US and MRI are necessary (Appendix Fig A5). Hysteroscopy may show the extent or multifocality of the lesion and allows tissue




FIG 6. High-risk GTN treatment to remission. ^aBest practice. ^bMost often used, but other multichemotherapy schedules are possible, reassuring on fertility; in selected cases, referral to the fertility specialist might be appropriate. ^cEvidence uncertain. CO, cyclophosphamide and vincristine; CT, computed tomography; EMA, etoposide, MTX, and actinomycin-D; EP, etoposide and cisplatin; FIGO, International Federation of Gynecology and Obstetrics; GTD, gestational trophoblastic disease; GTN, gestational trophoblastic neoplasia; hCG, human chorionic gonadotropin; IT-MTX, intrathecal MTX; MRI, magnetic resonance imaging; MTX, methotrexate.

collection for diagnosis and ancillary techniques. In patients wishing to retain fertility, follow-up with hysteroscopy, hCG measurements, and imaging is advised. There is no evidence available that guides optimal length of follow-up or frequency of imaging. For those patients with completed families, hysterectomy is advised as the APSN can be asymptotically present in the myometrium and can develop into ETT. If subsequent histologic examination shows no ETT/PSTT and either just APSN or no residual APSN, the patient can be discharged. However, if ETT/PSTT is present, then those guidelines should be followed (Appendix Figs A6 and A7).

PSTT/ETT should be suspected in women with normal or only slightly elevated hCG levels in comparison with the volume of visible disease on imaging (Appendix Fig A6). Tissue should be obtained from the tumor and sent for specialist review. In difficult cases, histology review by a second expert should be considered. National or international MDT meetings can help to reach an accurate diagnosis.⁴³ If PSTT or ETT is confirmed, imaging of the brain, chest, and abdomen should be performed. The FIGO scoring system (Appendix Table A1) is *not* applicable for PSTT/ETT. Instead, treatment is determined by the FIGO 2000 stage (Appendix Table A2) and by the interval from the end of the last known or causative pregnancy to diagnosis (Appendix Fig A7). Stage IV disease or an interval longer than 48 months

are two independent adverse prognostic factors for survival.⁴⁴⁻⁴⁶ In patients with stage I disease with an interval of <48 months, hysterectomy with salpingectomy is indicated. In all other cases, surgery followed by 12-16 weeks platinum-based chemotherapy is advised. Pembrolizumab or high-dose chemotherapy can be considered.⁴⁷ PSTT and ETT can be indolent diseases, and the antecedent pregnancy is not necessarily the origin of the PSTT or ETT. Genetics can be used to determine the origin of the disease to define the interval with the causative pregnancy.⁴⁸ Fertility-sparing surgery should be considered experimental as limited reports show that because of poor visualization of intrauterine disease, surgical margins are often not free after fertility-sparing surgery, still requiring salvage hysterectomy.⁴⁹ Registration in the international database for PSTT and ETT is strongly advised.

Follow-Up After Chemotherapy

In low-risk GTN, after confirmation of a normal hCG, at least 1 year of monthly hCG measurements is advised (Appendix Fig A8). Remaining lesion(s) on imaging should not be treated if hCG is normal. Risk of recurrence depends on histology (higher after choriocarcinoma) and the presence of lung metastases at presentation.⁵⁰ Most recurrences occur in the first year.⁵¹

Fertility is not harmed after treatment for low-risk GTN.⁴⁹ Fertility after EMA/CO is generally unchanged,⁵² but increased age at the time of starting treatment is an important factor. Early pregnancy can make diagnosis of recurrence difficult. The initially exponentially rising hCG levels seen with healthy pregnancies should help differentiate this from recurrence. US around 6–7 weeks can exclude a new molar pregnancy. The risk of a second molar pregnancy is around 1% for CHM and for PHM much lower.⁵³ There was no consensus on the use of placental review after the subsequent pregnancy. Six weeks after the end of pregnancy, hCG should have normalized based on small series and a repeat hCG is recommended at this time to ensure no reactivation of GTN.⁵⁴

After completion of high- and ultrahigh-risk GTN treatment, early post-treatment imaging should be obtained (Appendix Fig A9). Residual lesions do not appear to be predictive of recurrence and do not require removal if the serum hCG is normal. However, in the event of serially rising hCG indicating relapse, new imaging can then be compared with the post-treatment imaging. This comparison may reveal one growing lesion which can be surgically removed to effect a cure.⁵⁵ Protocols for hCG follow-up varied in frequency and duration between GTD centers. However, consensus was reached to monitor the hCG at least monthly for a year or more after 4–8 weeks of normal hCG values after completion of treatment. During follow-up, pregnancy is discouraged although early pregnancy is not associated with a higher risk of recurrence or unfavorable pregnancy outcome.⁵⁶ In a study among 255 women conceiving within 12 months after GTN treatment, 73.3% of live births were reported, with no increased risk of miscarriage or recurrence.⁵⁷ However, a higher risk of miscarriage in the first 6 months after treatment has been reported in another study⁵⁸ and in a meta-analysis. This meta-analysis including 23 studies showed an incidence of miscarriage of 15.5% after chemotherapy and a significantly higher occurrence in pregnancies <6 months after the end of chemotherapy.⁵⁹ Since most recurrences will occur in the first year of monitoring,⁵¹ it seems sensible to avoid conception during this time. Any form of contraception can be used. Discussion regarding recovery from a temporary chemotherapy-induced menopause is helpful to deal with fertility and timing of subsequent pregnancies. Assisted reproductive technology (ART) should not be withheld although reproductive outcomes in secondary infertile couples undergoing in vitro fertilization/intracytoplasmic sperm injection treatment were shown to be less favorable with a reduced live birth rate (34.1% v 66.7%).⁶⁰ Women can sometimes receive support from other women dealing with GTN.⁶¹

The optimal follow-up after PSTT/ETT treatment is currently unclear. Monitoring of serum hCG or other biomarkers such as human placental lactogen, especially if elevated before treatment, can be helpful. Imaging is advised in all patients except stage one patients diagnosed within <4.8 months of the causative pregnancy. No data on the value of imaging after

PSTT or ETT exist, but a suggested schedule is provided in Appendix Figure A10.

Diagnosis and Management of Recurrent GTN

A new pregnancy should always be excluded first when recurrence is suspected based on a rising hCG level (Appendix Fig A11). Imaging is necessary to define disease extent and differentiate resectable from nonresectable disease. A FDG-PET-CT can sometimes be helpful to exclude multiple metastases.⁶² Normalization of hCG after surgical resection may avoid the need for chemotherapy. If the recurrence is not visible on imaging or considered nonresectable, multiagent chemotherapy is the only proven effective option in relapsed low-risk GTN.^{35,63} The role of second single-agent treatment to salvage a patient who has relapsed after successful remission to another single-agent treatment is unclear.⁶⁴ In relapsed high-risk GTN, surgery is often less beneficial because the disease is more widespread, but still important to consider.^{9,65}

Patients should be extensively discussed for individualized surgical plans such as pulmonary resection, craniotomy, or resection of liver metastases.

If the surgical procedure does not lead to hCG normalization or there is nonresectable disease, then patients who have relapsed after EMA/CO should be offered platinum-based chemotherapy (Appendix Fig A12). After failure to this treatment or FAEV, anti-PD-1 immunotherapy is indicated (Appendix Fig 13).⁶⁶ Immunotherapy is quickly becoming more important. The number of patients treated with such agents is growing, and response rates seems to be around 70%. This is why these treatments have been investigated earlier in the disease, for example, in the TROPHAMET phase I to II trial, showing a promising alternative for multiagent chemotherapy. After failure of previous immunotherapy, either a rechallenge or combination with chemotherapy can be tried. In selected patients with a response to platinum/etoposide schedules, high-dose chemotherapy can still be beneficial.⁴⁷ If the hCG is increasing despite rechallenge with platinum and etoposide, the only treatment options currently remaining are clinical trials or palliation. In cases with mixed response, salvage surgery or radiotherapy can be considered. Cured patients should be offered surveillance for at least 2 years.

In conclusion, our international multidisciplinary panel has produced a set of globally agreed definitions and guidelines for the diagnosis, management, and follow-up of patients with GTD. The widespread adoption of these standards across the world should improve the outcome of women with GTD and reduce unwanted practice variation and unnecessary deaths. The flow diagrams and definitions may also help to educate and train health professionals around the world and help new centers to be established. Finally, this work will help to ensure that data reported between centers are more comparable to facilitate future research.

AFFILIATIONS

¹Department of Gynaecologic Oncology, Centre of Gynaecologic

Oncology Amsterdam, Amsterdam, the Netherlands

²Department of Gynecology, Center of Oncological Surgery, Charité-University Hospital Berlin, Berlin, Germany

³Institut Bergonié, Bordeaux, France

⁴New England Trophoblastic Disease Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

⁵Department of Surgery & Cancer, Charing Cross Hospital Gestational Trophoblastic Disease Center, Charing Cross Hospital Campus of Imperial College London, London, United Kingdom

CORRESPONDING AUTHOR

Christianne Lok, MD, PhD; e-mail: c.lok@nki.nl.

EQUAL CONTRIBUTION

C.L. and N.v.T. shared first authorship. R.B. and M.S. shared last authorship.

SUPPORT

Supported by the European Society of Gynaecological Oncology, which provided an epidemiologist and a project manager who were involved in the development of the guidelines.

REFERENCES

- Braga A, Lopes R, Campos V, et al: The impact of the distance traveled between residence and gestational trophoblastic neoplasia reference center and clinical outcomes in Brazilian women. *Gynecol Oncol* 176:130-138, 2023
- Joneborg U, Bergamini A, Wallin E, et al: European multidisciplinary tumor boards support cross-border networking and increase treatment options for patients with rare gynecological tumors. *Int J Gynecol Cancer* 33:1621-1626, 2023
- World Development Indicators: The World Development Bank, 2023. <https://wdi.worldbank.org/tables>
- Fertility GBD, Forecasting C: Global fertility in 204 countries and territories, 1950-2021, with forecasts to 2100: A comprehensive demographic analysis for the Global Burden of Disease Study 2021. *Lancet* 403:2057-2099, 2024
- Lok C, van Trommel N, Massuger L, et al; Clinical Working Party of the E: Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease. *Eur J Cancer* 130: 228-240, 2020
- Ngan HY, Bender H, Benedet JL, et al: Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. *Int J Gynaecol Obstet* 83:175-177, 2003 (suppl 1)
- Lok C, Frijstein M, van Trommel N: Clinical presentation and diagnosis of gestational trophoblastic disease. *Best Pract Res Clin Obstet Gynaecol* 74:42-52, 2021
- Verri D, Pasciuto T, Epstein E, et al: Gestational Trophoblastic Neoplasia ultrasound assessment: TITANIUM study. *Int J Gynecol Cancer* 29:1216-1220, 2019
- Coopmans L, Larsson A, Joneborg U, et al: Surgical management of gestational trophoblastic disease. *Gynecol Obstet Invest* 89:214-229, 2024
- Eysbouts YK, Massuger L, Int'Hout J, et al: The added value of hysterectomy in the management of gestational trophoblastic neoplasia. *Gynecol Oncol* 145:536-542, 2017
- Kaur B: Pathology of gestational trophoblastic disease (GTD). *Best Pract Res Clin Obstet Gynaecol* 74:3-28, 2021
- McMahon LM, Joyce CM, Cuthill L, et al; hCG working party of the EOTTD: Measurement of hCG in women with gestational trophoblastic disease. *Gynecol Obstet Invest* 89:178-197, 2024
- Tan A, Van der Merwe AM, Low X, et al: Familial HCG syndrome: A diagnostic challenge. *Gynecol Oncol Rep* 10:47-48, 2014
- Cole LA: Familial HCG syndrome. *J Reprod Immunol* 93:52-57, 2012
- Sebire NJ, Foskett M, Paradinas FJ, et al: Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin. *Lancet* 359:2165-2166, 2002
- European Organisation for Treatment of Trophoblastic Diseases. www.eottd.org
- International Society for the Study of Trophoblastic Diseases. www.isstd.org
- Price JM, Lo C, Abdi S, et al: The role of Computed tomography scanning of the thorax in the initial assessment of gestational trophoblastic neoplasia. *Int J Gynecol Cancer* 25:1731-1736, 2015
- McGrath S, Short D, Harvey R, et al: The management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU (l-1). *Br J Cancer* 102:810-814, 2010
- FIGO Oncology Committee: FIGO staging for gestational trophoblastic neoplasia 2000. *Int J Gynaecol Obstet* 77:285-287, 2002
- Lawrie TA, Alazzam M, Tidy J, et al: First-line chemotherapy in low-risk gestational trophoblastic neoplasia. *Cochrane database Syst Rev* 2016:CD007102, 2016
- Osborne RJ, Filiaci V, Schink JC, et al: Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: A gynecologic oncology group study. *J Clin Oncol* 29:825-831, 2011
- Petrilli ES, Twiggs LB, Blessing JA, et al: Single-dose actinomycin-D treatment for nonmetastatic gestational trophoblastic disease. A prospective phase II trial of the Gynecologic Oncology Group. *Cancer* 60:2173-2176, 1987
- Schink JC, Filiaci V, Huang HQ, et al: An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275. *Gynecol Oncol* 158:354-360, 2020
- Osborne RJ, Filiaci VL, Schink JC, et al: Second curettage for low-risk nonmetastatic gestational trophoblastic neoplasia. *Obstet Gynecol* 128:535-542, 2016
- Alazzam M, Hancock BW, Tidy J: Role of hysterectomy in managing persistent gestational trophoblastic disease. *J Reprod Med* 53:519-524, 2008
- Cortes-Charry R, Hennah L, Froeling FEM, et al: Increasing the human chorionic gonadotrophin cut-off to ≤ 1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy. *ESMO Open* 6:100110, 2021
- Covens A, Filiaci VL, Burger RA, et al: Phase II trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. *Cancer* 107:1280-1286, 2006
- Winter MC, Tidy JA, Singh K, et al: Efficacy analysis of single-agent carboplatin AUC4 2-weekly as second-line therapy for methotrexate-resistant (MTX-R) low risk gestational trophoblastic neoplasia (GTN). *Gynecol Oncol* 175:66-71, 2023
- Mora PAR, Sun SY, Velarde GC, et al: Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia? *Gynecol Oncol* 153:277-285, 2019
- You B, Bolze PA, Lotz JP, et al: Avelumab in patients with gestational trophoblastic tumors with resistance to single-agent chemotherapy: Cohort A of the TROPHIMMUN phase II trial. *J Clin Oncol* 38:3129-3137, 2020

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at DOI <https://doi.org/10.1200/JCO-24-02326>.

AUTHOR CONTRIBUTIONS

Conception and design: Christianne Lok, Nienke van Trommel, Elena Ioana Braicu, Ross Berkowitz, Michael Seckl

Administrative support: Christianne Lok

Collection and assembly of data: All authors

Data analysis and interpretation: All authors

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

ACKNOWLEDGMENT

A complete list of the EOTTD-ESGO-GCIG-ISSTD Guideline Committee members can be found in [Appendix 1](#). The list of reviewers is presented in [Appendix Table A6](#).

32. Braga A, Paiva G, Ghorani E, et al: Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: A multicentre, retrospective, cohort study. *Lancet Oncol* 22: 1188-1198, 2021
33. Lybol C, Sweep FC, Harvey R, et al: Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. *Gynecol Oncol* 125: 576-579, 2012
34. Couder F, Massardier J, You B, et al: Predictive factors of relapse in low-risk gestational trophoblastic neoplasia patients successfully treated with methotrexate alone. *Am J Obstet Gynecol* 215:80 e1-e80 e7, 2016
35. Alifrangis C, Agarwal R, Short D, et al: EMA/CO for high-risk gestational trophoblastic neoplasia: Good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. *J Clin Oncol* 31: 280-286, 2013
36. Savage P, Kelpanides I, Tuthill M, et al: Brain metastases in gestational trophoblast neoplasia: An update on incidence, management and outcome. *Gynecol Oncol* 137:73-76, 2015
37. Savage P, Winter M, Parker V, et al: Demographics, natural history and treatment outcomes of non-molar gestational choriocarcinoma: A UK population study. *BJOG* 127:1102-1107, 2020
38. Ji M, Jiang S, Zhao J, et al: Efficacies of FAEV and EMA/CO regimens as primary treatment for gestational trophoblastic neoplasia. *Br J Cancer* 127:524-530, 2022
39. Xiao C, Yang J, Zhao J, et al: Management and prognosis of patients with brain metastasis from gestational trophoblastic neoplasia: A 24-year experience in Peking union medical college hospital. *BMC Cancer* 15:318, 2015
40. Kaur B, Short D, Fisher RA, et al: Atypical placental site nodule (APSN) and association with malignant gestational trophoblastic disease; a clinicopathologic study of 21 cases. *Int J Gynecol Pathol* 34:152-158, 2015
41. Hui P, Webster F, Baergen RN, et al: Dataset for the reporting of gestational trophoblastic neoplasia: Recommendations from the International Collaboration on Cancer Reporting (ICCR). *Int J Gynecol Pathol* 41:S34-S43, 2022 (suppl 1)
42. Jeremie G, Allias F, Trecourt A, et al: Molecular analyses of chorionic-type intermediate trophoblastic lesions: Atypical placental site nodules are closer to placental site nodules than epithelioid trophoblastic tumors. *Mod Pathol* 36:100046, 2023
43. Marquina G, Szcwycyk G, Goffin F: The rare of the rarest: Placental site trophoblastic tumor, epithelioid trophoblastic tumor, atypical placental site nodule. *Gynecol Obstet Invest* 89:239-246, 2024
44. Frijstein MM, Lok CAR, van Trommel NE, et al: Management and prognostic factors of epithelioid trophoblastic tumors: Results from the international society for the study of trophoblastic diseases database. *Gynecol Oncol* 152:361-367, 2019
45. Schmid P, Nagai Y, Agarwal R, et al: Prognostic markers and long-term outcome of placental-site trophoblastic tumours: A retrospective observational study. *Lancet* 374:48-55, 2009
46. Froeling FEM, Ramaswami R, Papanastopoulos P, et al: Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours. *Br J Cancer* 120:587-594, 2019
47. Frijstein MM, Lok CAR, Short D, et al: The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia. *Eur J Cancer* 109: 162-171, 2019
48. Fisher RA, Maher GJ: Genetics of gestational trophoblastic disease. *Best Pract Res Clin Obstet Gynaecol* 74:29-41, 2021
49. Joneborg U, Coopmans L, van Trommel N, et al: Fertility and pregnancy outcome in gestational trophoblastic disease. *Int J Gynecol Cancer* 31:399-411, 2021
50. Frijstein MM, Lok C, van Trommel NE, et al: Lung metastases in low-risk gestational trophoblastic neoplasia: A retrospective cohort study. *BJOG* 127:389-395, 2020
51. Balachandran K, Salawu A, Ghorani E, et al: When to stop human chorionic gonadotropin (hCG) surveillance after treatment with chemotherapy for gestational trophoblastic neoplasia (GTN): A national analysis on over 4,000 patients. *Gynecol Oncol* 155:8-12, 2019
52. Lok CA, van der Houwen C, ten Kate-Booij MJ, et al: Pregnancy after EMA/CO for gestational trophoblastic disease: A report from the Netherlands. *BJOG* 110:560-566, 2003
53. Eagles N, Sebire NJ, Short D, et al: Risk of recurrent molar pregnancies following complete and partial hydatidiform moles. *Hum Reprod* 31:1379, 2016
54. Faiman C, Ryan RJ, Zwirek SJ, et al: Serum FSH and HCG during human pregnancy and puerperium. *J Clin Endocrinol Metab* 28:1323-1329, 1968
55. Bouchard-Fortier G, Ghorani E, Short D, et al: Following chemotherapy for gestational trophoblastic neoplasia, do residual lung lesions increase the risk of relapse? *Gynecol Oncol* 158:698-701, 2020
56. Blagden SP, Foskett MA, Fisher RA, et al: The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours. *Br J Cancer* 86:26-30, 2002
57. Williams J, Short D, Dayal L, et al: Effect of early pregnancy following chemotherapy on disease relapse and fetal outcome in women treated for gestational trophoblastic neoplasia. *J Reprod Med* 59:248-254, 2014
58. Garcia MT, Lin LH, Fushida K, et al: Pregnancy outcomes after chemotherapy for trophoblastic neoplasia. *Rev Assoc Med Bras* 62:837-842, 2016
59. Madi JM, Paganella MP, Litvin IE, et al: Perinatal outcomes of first pregnancy after chemotherapy for gestational trophoblastic neoplasia: A systematic review of observational studies and meta-analysis. *Am J Obstet Gynecol* 226:633-645.e8, 2022
60. Cai X, Zhang M, Huang C, et al: Association between gestational trophoblastic disease (GTD) history and clinical outcomes in in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles. *Reprod Biol Endocrinol* 20:27, 2022
61. Garner E, Goldstein DP, Berkowitz RS, et al: Psychosocial and reproductive outcomes of gestational trophoblastic diseases. *Best Pract Res Clin Obstet Gynaecol* 17:959-968, 2003
62. Dhillon T, Palmieri C, Sebire NJ, et al: Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia. *J Reprod Med* 51:879-887, 2006
63. Albright BB, Ellett T, Knochenhauer HE, et al: Treatments and outcomes in high-risk gestational trophoblastic neoplasia: A systematic review and meta-analysis. *BJOG* 130:443-453, 2023
64. Jareemit N, Horowitz NS, Goldstein DP, et al: Outcomes for relapsed versus resistant low risk gestational trophoblastic neoplasia following single-agent chemotherapy. *Gynecol Oncol* 159: 751-757, 2020
65. Hanna RK, Soper JT: The role of surgery and radiation therapy in the management of gestational trophoblastic disease. *Oncologist* 15:593-600, 2010
66. Baas IO, Westermann AM, You B, et al: Immunotherapy for GTN: A new paradigm. *Gynecol Obstet Invest* 89:230-238, 2024

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD)–European Society of Gynaecologic Oncology (ESGO)–Gynecologic Cancer InterGroup (GCIG)–International Society for the Study of Trophoblastic Diseases (ISSTD)

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](#)).

Elena Ioana Braicu

Honoraria: AstraZeneca, North Eastern German Society for Gynecologic Oncology, AbbVie

Consulting or Advisory Role: MSD, Immunogen, AbbVie, GlaxoSmithKline, Myriad Genetics, IQvia (Inst), Pharmaand, Tori Biotherapeutics, Tubulis GmbH

Research Funding: AstraZeneca (Inst), GlaxoSmithKline (Inst), Clovis Oncology (Inst), MSD (Inst), Tesaro (Inst), Roche Molecular Diagnostics

(Inst), AbbVie (Inst), Iqvia (Inst), Daiichi Sankyo Europe GmbH (Inst), Eisai Europe (Inst)

Travel, Accommodations, Expenses: AstraZeneca

Uncompensated Relationships: North Eastern German Society of Gynecologic Oncology (NOGGO eV)

Michael Seckl

Consulting or Advisory Role: Bristol Myers Squibb

Expert Testimony: Teva

Travel, Accommodations, Expenses: Bristol Myers Squibb

No other potential conflicts of interest were reported.

APPENDIX 1**EOTTD-ESGO-GCIG-ISSTD Guideline Committee in Alphabetical Order:**

Inge O. Baas, Medical Oncologist, Department of Medical Oncology, University Medical Center Utrecht B02-225 Utrecht, the Netherlands.

Alice Bergamini, Gynecologist, Department of Obstetrics and Gynecology, IRCCS Ospedale San Raffaele & Faculty of Medicine, Vita-Salute San Raffaele University, Milan, Italy.

Miguel Henriques Abreu, Professor, Medical Oncologist, Department of Medical Oncology, Portuguese Institute of Oncology of Porto, Porto, Portugal.

Pierre-Adrien Bolze, Gynecologic Oncologist, French Reference Center for Trophoblastic Tumors, Hospices Civils de Lyon, Lyon Sud University Hospital, France.

Genevieve Bouchard-Fortier, Gynecologic Oncologist, Department of Obstetrics & Gynecology, University of Toronto, Toronto, ON, Canada, Division of Gynecologic Oncology, Princess Margaret Cancer Center/University Health Network and Sinai Health System, Toronto, ON, Canada.

Antonio Braga, Professor of Obstetrics, Department of Obstetrics, Vassouras University Rio de Janeiro, Maternity School of Rio de Janeiro, Director of Rio de Janeiro Trophoblastic Disease Center, Brasil.

Maria Stephanie Fay S. Cagayan, MD, PhD, Department of Pharmacology and Toxicology and Department of Obstetrics and Gynecology, University of the Philippines, Manila, Philippines.

Antonio Casado, Gynecologic Oncologist, Department of Medical Oncology, Hospital Clínico San Carlos, Department of Medicine, School of Medicine, Universidad Complutense de Madrid (UCM), IdiSSC, EURACAN Referral Center, Madrid, Spain.

Min Chul Choi, Gynecologic Oncologist, Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, South Korea.

John Coulter, Gynecologist, Department of Obstetrics and Gynecology, University College Cork, Ireland.

Kevin Elias, Section of Gynecologic Oncology, Obstetrics and Gynecology Institute, Taussig Cancer Institute, Cleveland Clinic Foundation, Case Comprehensive Cancer Center, Cleveland, OH, USA.

Hind H. Elmalik, Consultant Medical Oncology, Hamad Medical Corporation (HMC), National Center for Cancer Care and Research (NCCCR), Qatar.

Andrea Garrett, Gynecologic Oncologist, The Wesley Hospital and Royal Brisbane and Women's Hospital, Brisbane, Australia.

Ehsan Ghorani, Department of Surgery and Cancer, Imperial College London, United Kingdom.

Andrea Gmur, Gynecologist, Department of Obstetrics and Gynecology, Bern University Hospital and University of Bern, Switzerland.

Frederic Goffin, Department of Obstetrics and Gynecology, University Hospital and Hospital of la Citadelle of Liège, Liège, Belgium.

Francois Goffier, Gynecologic Oncologist, French reference Center for trophoblastic tumors, Hospices Civils de Lyon, Lyon Sud University Hospital, Lyon 1 University, Lyon, France.

Neil Horowitz, Obstetrician/Gynecologist, New England Trophoblastic Disease Center, Brigham and Women's Hospital, Harvard Medical School, USA.

Ulrika Joneborg, Gynecologic Oncologist, Department of Women's and Children's Health, Karolinska Institutet, Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden.

Baljeet Kaur, Consultant Cellular Pathologist, North West London Pathology (NWLP)

Regional Lead for Gestational Trophoblast Pathology (GTD) and Malignant Ovarian Germ Cell (MOGCT) Service and Honorary Senior Lecturer, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, W6 8RF, United Kingdom.

Philip Tonui Kipkirui, Gynaecologic Oncology, Department of Gynecologic Oncology, Moi University School of Medicine, Eldoret, Kenya.

Jacob Korach, Department of Gynecologic Oncology, Sheba Medical Center, Tel Aviv University, Israel.

Xin Lu, Department of Gynecologic Oncology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.

Izildinha Maesta, Gynecologist, Department of Gynecology and Obstetrics, Botucatu Trophoblastic Disease Center, Sao Paulo State University (UNESP), Medical School, Botucatu, SP, Brazil.

Giorgia Mangili, Gynecologist, Obstetrics and Gynecology Unit IRCCS San Raffaele Hospital, Milan, Italy.

Gloria Marquina, Medical Oncologist, Department of Medical Oncology, Hospital Clínico San Carlos, Department of Medicine, School of Medicine, Universidad Complutense de Madrid (UCM), IdiSSC, EURACAN Referral Center, Madrid, Spain.

Jerome Massardier, Gynecologist, Department of Obstetrics and Gynecology, Femme Mere Enfant University Hospital and Hospices Civils de Lyon, French Trophoblastic Disease Reference Center, Lyon Sud University Hospital, Lyon, France.

Hextan Y.S. Ngan, Gynecologist, Department of Obstetrics and Gynecology, The University of Hong Kong, Queen Mary Hospital, Hong Kong.

Ray Osborne, Gynecological Oncologist, Sunnybrook Health Sciences Center, Toronto, ON, Canada, Canada.

Nelleke P.B. Ottevanger, Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein 8, 6500 HB Nijmegen, the Netherlands.

Sinan Ozalp, Founder and Former President of Society, Department of Obstetrics and Gynecology and Gynecologic Oncology Unit, Medical Faculty, Eskisehir Osmangazi University, Eskisehir, Turkey.

Naveed Sarwar, Department of Medical Oncology, Charing Cross Hospital Gestational Trophoblastic Disease Center, Charing Cross Hospital Campus of Imperial College London, Fulham Palace Rd, London W6 8RF, United Kingdom

Paradan K. Sekharan, Former Professor and Head, Department of Obstetrics & Gynecology, Governmental Medical College, Kozhikode, Kerala, India.

Franziska Siegenthaler, Gynecologist, Department of Obstetrics and Gynecology, Bern University Hospital and University of Bern, Switzerland.

Olesya Solheim, Consultant, Gynecology and Obstetrics, Department of Gynecological Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Norway.

Lone Sunde, Professor, Consultant, Department of Clinical Genetics and Clinical Cancer Research Center and Department of Clinical Medicine, Aalborg University Hospital, Department of Biomedicine, Aarhus University, Denmark.

Fred C.G.J. Sweep, Department of Laboratory medicine, Radboud University Medical Center, Geert Grooteplein 8, 6500 HB Nijmegen, the Netherlands.

Grzegorz Szewczyk, Gynecologic Oncologist, Department of Obstetrics, Gynecology and Gynecological Oncology, Mazovian Voivodship Hospital, St John Paul's the 2nd memorial in Siedlce, Poland, Department of Biophysics, Physiology and Pathophysiology, Medical University of Warsaw, Poland.

Manuela Undurraga, Gynecologic Oncologist, Department Femme, Enfant et Adolescent, Hôpitaux Universitaires de Genève, Department of Obstetrics and Gynecology, Université de Genève, Switzerland.

Emelie Wallin, Gynecologic Oncologist, Department of Oncology and Pathology, Karolinska Institutet, Department of Pelvic Cancer, Karolinska University Hospital, Sweden.

Matthew C. Winter, Sheffield Trophoblastic Disease Center, Weston Park Hospital, Sheffield Teaching Hospitals Foundation Trust, Director and Honorary Professor of Medical Oncology, Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, United Kingdom

Eiko Yamamoto, Department of gynecologic oncology, Nagoya University Graduate School of Medicine, Department of Healthcare Administration, Japan.

Benoit You, Medical Oncologist, French Reference Center for Trophoblastic Tumors, Hospices Civils de Lyon, Lyon Sud University Hospital, Lyon 1 University, Lyon, France.

Emelie Wallin, Medical Oncologist, Department of Oncology and Pathology, Karolinska Institutet, Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden.

Anneke Westermann, Department of Medical Oncology, Amsterdam University Medical Centers, Amsterdam, the Netherlands.

Yang Xiang, Gynecologist, Department of Gynecol Oncol, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China.

Ignacio Zapardiel, Gynecologic Oncologist, Gynecologic Oncology Unit, La Paz University Hospital, Madrid, Spain.




FIG A1. Development process.




FIG A2. Suspected complete hydatidiform mole with viable fetus. ^aUS can be highly suggestive but is not diagnostic of CHM. ^bBest practice. CHM, complete hydatidiform mole; GTD, gestational trophoblastic disease; GTN, gestational trophoblastic neoplasia; hCG, human chorionic gonadotropin; HM, hydatidiform mole; PHM, partial hydatidiform moles; US, ultrasound.




FIG A3. Postmole GTN treatment. ^aBest practice. FIGO, International Federation of Gynecology and Obstetrics; GTD, gestational trophoblastic disease; GTN, gestational trophoblastic neoplasia; MDT, multidisciplinary team.




FIG A4. Ultrahigh-risk GTN treatment to remission. ^aBest practice. ^bEvidence uncertain. ^cFavored in some regions. CO, cyclophosphamide and vincristine; EA, etoposide and actinomycin-D; EP, etoposide, methotrexate, actinomycin-D; EP, etoposide and cisplatin; FAEV, floxuridine, actinomycin-D, etoposide, and vincristine; GTN, gestational trophoblastic neoplasia; hCG, human chorionic gonadotropin; MRI, magnetic resonance imaging; MTX, methotrexate.




FIG A5. APSN. Only small case series, so low level of evidence. ^aBest practice. ^bFertility-sparing surgery is experimental and should only be performed in the GTD center by experienced surgeons in selected cases. APSN, atypical placental site nodule; CT, computed tomography; ETT, epithelioid trophoblastic tumor; GTD, gestational trophoblastic disease; hCG, human chorionic gonadotropin; MRI, magnetic resonance imaging; PSTT, placental site trophoblastic tumor; US, ultrasound.




FIG A6. Diagnosis of PSTT/ETT. ^aBest practice. ^bBased on the FIGO 2000 staging system. CT, computed tomography; ETT, epithelioid trophoblastic tumor; FIGO, International Federation of Gynecology and Obstetrics; GTD, gestational trophoblastic disease; hCG, human chorionic gonadotropin; ISSTD, International Society for the Study of Trophoblastic Disease; MRI, magnetic resonance imaging; PSTT, placental site trophoblastic tumor.




FIG A7. Treatment of PSTT/ETT. ^aBest practice. ^bOr other PD-1–targeted therapies, if available. EMA/EP, etoposide, methotrexate, actinomycin-D, etoposide, and cisplatin; ETT, epithelioid trophoblastic tumor; HDC, high-dose chemotherapy; pembro, pembrolizumab; PSTT, placental site trophoblastic tumor; TE, paclitaxel and etoposide; TP, paclitaxel and cisplatin.




FIG A8. Follow-up after low-risk GTN. ^aBest practice. ART, assisted reproductive technology; GTD, gestational trophoblastic disease; GTN, gestational trophoblastic neoplasia; hCG, human chorionic gonadotropin; HM, hydatidiform mole.




FIG A9. Follow-up after high-risk and ultrahigh-risk GTN. ^aBest practice. ART, assisted reproductive technology; GTD, gestational trophoblastic disease; GTN, gestational trophoblastic neoplasia; hCG, human chorionic gonadotropin; ISSTD, International Society for the Study of Trophoblastic Diseases.




FIG A10. Follow-up after PSTT/ETT treatment. CT, computed tomography; ETT, epithelioid trophoblastic tumor; GTD, gestational trophoblastic disease; GTN, gestational trophoblastic neoplasia; hCG, human chorionic gonadotropin; MRI, magnetic resonance imaging; PSTT, placental site trophoblastic tumor.




FIG A11. Recurrence after remission of low-risk GTN after treatment with one or two lines of monotherapy with MTX or Act-D. ^aBest practice. ^bIncluding incidental second molar pregnancy. ^cIn the case of uterine disease. ^dThere are limited published data on the use of second-line monotherapy after relapse after one single agent. Act-D, actinomycin-D; CT, computed tomography; EMA/CO, etoposide, methotrexate, actinomycin-D, cyclophosphamide, and vincristine; GTD, gestational trophoblastic disease; GTN, gestational trophoblastic neoplasia; hCG, human chorionic gonadotropin; MRI, magnetic resonance imaging; MTX, methotrexate; PET, positron emission tomography; US, ultrasound.




FIG A12. Recurrence of high-risk GTN after treatment with EMA/CO or platinum-free equivalent. ^aBest practice. ^bIn the case of uterine disease. ^cOnly used in China. CT, computed tomography; EMA/EP, etoposide, methotrexate, actinomycin-D, etoposide, and cisplatin; FAEV, floxuridine, actinomycin-D, etoposide, and vincristine; GTD, gestational trophoblastic disease; GTN, gestational trophoblastic neoplasia; hCG, human chorionic gonadotropin; MRI, magnetic resonance imaging; PET, positron emission tomography; TE, paclitaxel and etoposide; TP, paclitaxel and cisplatin; US, ultrasound.




FIG A13. Recurrence of nonresectable disease after EMA/EP or TE/TP or FAEV. ^aBest practice. ^bThere are no published data to guide the use of immunotherapy after long-term remission on previous immunotherapy. ^cNo data on high dose after immunotherapy. EMA/EP, etoposide, methotrexate, actinomycin-D, etoposide, and cisplatin; FAEV, floxuridine, actinomycin-D, etoposide, and vincristine; GTD, gestational trophoblastic disease; hCG, human chorionic gonadotropin; NGS, next generation sequencing; TE, paclitaxel and etoposide; TP, paclitaxel and cisplatin.

TABLE A1. FIGO Scoring System

Score	0	1	2	4
Age, years	<40	≥40	–	–
Antecedent pregnancy	Mole	Miscarriage	Term	–
Interval from index pregnancy, months	<4	4 to <7	7 to <13	≥13
Pretreatment serum hCG, IU/mL	<1,000	1,000 to <10,000	10,000-100,000	≥100,000
Largest tumor size (including uterus)	–	3 to <5 cm	≥5 cm	–
Site of metastases	Lung	Spleen, kidney	GI	Liver, brain
Metastases, No.	–	1-4	5-8	>8
Previous failed chemotherapy	–	–	Single drug	≥2 drugs

Abbreviations: FIGO, International Federation of Gynaecology and Obstetrics; hCG, human chorionic gonadotropin.

TABLE A2. FIGO staging system

Stage	Description
I	Gestational trophoblastic tumors strictly confined to the uterine corpus
II	Gestational trophoblastic tumors extending to the adnexa or to the vagina but limited to the genital structures
III	Gestational trophoblastic tumors extending to the lungs, with or without genital tract involvement
IV	All other metastatic sites

Abbreviation: FIGO, International Federation of Gynaecology and Obstetrics.

TABLE A3. Definitions of GTD

Term	Definition
GTD	All forms of premalignant or malignant neoplasia arising from the cytotrophoblast, syncytiotrophoblast, or intermediate trophoblast
GTN	All malignant forms of GTD including invasive mole, gestational choriocarcinoma, PSTT, and ETT
Low-risk GTN	FIGO score <7 (FIGO 0-6)
High-risk GTN	FIGO score ≥7 (FIGO 7-12)
Ultrahigh-risk GTN	FIGO score ≥13
Normalization of hCG	2 normal consecutive hCG levels at least 1 week apart within the normal range of the assay in a nonpregnant woman (preferably measured in a reference laboratory for hCG)
Remission after chemotherapy of hCG-secreting GTN	Normal hCG over a period of at least 4 weeks after completing chemotherapy
Remission after treatment of non-hCG-secreting GTN (eg, PSTT/ETT)	No evidence of disease/progression on physical examination and/or on (serial) imaging and/or pathologic examination of removed (metastatic) disease sites at least 4 weeks after treatment completion
Unexplained persistent real low-level hCG (in the absence of a lesion)	Serum hCG above the detection level measured in at least >3 samples in >3 months
Chemotherapy resistance in low- or high-risk disease	
Primary resistance	hCG increases despite 2 courses of systemic agent or hCG plateaus (<10% decrease over 2 weeks) despite 3 courses of systemic treatment
Acquired resistance	hCG plateau (<10% decrease over 2 courses [4 weeks]) or rise (at least 2 values over 2 weeks) after initial response
Recurrent GTN	Increase in hCG on at least two consecutive occasions (at least 1 week apart) and above the reference level of GTD center and at least 4 weeks after cessation of treatment (including consolidation) and exclusion of new pregnancy

Abbreviations: ETT, epithelioid trophoblastic tumor; FIGO, International Federation of Gynecology and Obstetrics; GTD, gestational trophoblastic disease; GTN, gestational trophoblastic neoplasia; hCG, human chorionic gonadotropin; PSTT, placental site trophoblastic tumor.

TABLE A4. Requirements of a GTD center

Requirement
>5 patients should be discussed or treated in the center each year
At least one member of the GTD center should be a member of an international GTD society and regularly attend its meetings
The center should have an expert experienced in giving single-agent MTX and Act-D, EMA/CO, and EMA/EP (or equivalent)
The center should have (or easy access to) an expert pathologist; a nurse with special interest in GTD; a radiology department with CT, MRI, and interventional radiology; and an intensive care unit. Easy access to PET-CT would be desirable
The center should serve at least as a regional referral center for GTD

Abbreviations: Act-D, actinomycin-D; CT, computed tomography; EMA/CO, etoposide, MTX, Act-D, cyclophosphamide, and vincristine; EMA/EP, etoposide, MTX, Act-D, etoposide, and cisplatin; GTD, gestational trophoblastic disease; MRI, magnetic resonance imaging; MTX, methotrexate; PET, positron emission tomography.

TABLE A5. Dosing schedules

Drug	Dosage Regimen
MTX once every 2 weeks	
MTX with FA	MTX 1 mg/kg IM once daily on days 1, 3, 5, 7 or fixed-dose 50 mg once daily on days 1, 3, 5, 7 FA (leucovorin) 15 mg PO 24-30 hours after MTX once daily on days 2, 4, 6, 8
MTX alone	MTX 0.4 mg/kg/day once daily IV or IM days 1-5, not exceeding 25 mg/day
Actinomycin-D once every 2 weeks	
	1.25 mg/m ² IV bolus (max 2 mg) or 0.5 mg IV once daily for days 1-5
EMA/CO once every 2 weeks	
EMA	
Day 1	Actinomycin-D 0.5 mg IV once daily Etoposide 100 mg/m ² IV once daily MTX 300 mg/m ² IV once daily
Day 2	Actinomycin-D 0.5 mg IV once daily Etoposide 100 mg/m ² IV once daily Leucovorin 15 mg PO twice per day × 4 doses starting 24 hours after commencing MTX
CO	
Day 8	Vincristine 0.8 mg/m ² (max 2 mg) once daily Cyclophosphamide 600 mg/m ² once daily
TE/TP once every 4 weeks	
Day 1	Paclitaxel 135 mg/m ² IV once daily Cisplatin 60 mg/m ² IV once daily
Day 15	Paclitaxel 135 mg/m ² IV once daily Etoposide 150 mg/m ² IV once daily
EMA/EP once every 2 weeks	
Day 1	Actinomycin-D 0.5 mg IV once daily Etoposide 100 mg/m ² IV once daily MTX 300 mg/m ² IV once daily
Day 2	Leucovorin 15 mg PO twice daily × 4 doses starting 24 hours after commencing MTX
Day 8	Etoposide 150 mg/m ² IV once daily Cisplatin 75 mg/m ² IV once daily
Low-dose EP once weekly	
Day 1	Etoposide 100 mg/m ² IV once daily Cisplatin 20 mg/m ² IV once daily
Day 2	Etoposide 100 mg/m ² IV once daily Cisplatin 20 mg/m ² IV once daily
FAEV once every 3 weeks	
	Floxuridine 800-900 mg/m ² once daily IV days 1-5 Actinomycin-D 0.2 mg/m ² once daily IV days 1-5 Etoposide 100 mg/m ² once daily IV days 1-5 Vincristine 2 mg IV bolus, once on day 1
Immune checkpoint inhibition	
Avelumab	800 mg IV once every 2 weeks, 3 consolidation courses
Camrelizumab/apatinib	In each once every 4 weeks treatment cycle, camrelizumab IV once every 2 weeks and apatinib orally once per day
Pembrolizumab	200 mg once every 3 weeks until normalization, 5 cycles of consolidation
Pembrolizumab/ chemotherapy	Has been combined with TE/TP, EP, and FAEV, and pembrolizumab was continued for at least 4 months after completing combinations

Abbreviations: CO, cyclophosphamide and vincristine; EMA, etoposide, MTX, and actinomycin-D; EP, etoposide and cisplatin; FA, folinic acid; FAEV, floxuridine, actinomycin-D, etoposide, and vincristine; IM, intramuscular; IV, intravenous; MTX, methotrexate; PO, orally; TE, paclitaxel and etoposide; TP, paclitaxel and cisplatin.

TABLE A6. List of External Reviewers

Name	Specialty	Country
Cioffi Raffaella	Gynecologic Oncology, Obstetrics & Gynecology	Italy
Cortés Rafael	Obstetrics & Gynecology	Venezuela
de la Motte Rouge Thibault	Medical Oncology	France
Hemida Reda	Gynecologic Oncology	Egypt
Jamelot Mathieu	Medical Oncology	France
Kesic Vesna	Gynecologic Oncology	Serbia
Miedzińska Magdalena	Medical Oncology	Poland
Miller David	Gynecologic Oncology	USA
Morrison Shona	Nursing	Australia
Niimi Kaoru	Gynecologic Oncology	Japan
Patrier Sophie	Pathology	France
Pierre Marc Edy	Medical Oncology	Colombia
Rajaram Shalini	Gynecologic Oncology, Obstetrics & Gynecology	India
Rousset Pascal	Radiology	France
Rustin Gordon	Medical Oncology	United Kingdom
Sauthier Philippe	Gynecologic Oncology	Canada
Savage Philip	Medical Oncology	United Kingdom
Schink Julian	Gynecologic Oncology	United States
Slim Rima	Genetics	Canada
Tejada Berges Trevor	Gynecologic Oncology	Australia
Tsip Nataliya	Gynecologic Oncologist	Ukraine
Ulrikh Elena	Gynecologic Oncology, Obstetrics & Gynecology, Medical Oncology	Russia
Usui Hirokazu	Gynecologic Oncology, Obstetrics and Gynecology	Japan
Verheijen Rene	Gynecologic Oncology	France